Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Bruce Brockstein"'
Autor:
Alexa Bello, Mir B. Alikhan, Aparna Subramaniam, Zenab I. Yusuf, Bruce Brockstein, Vinod Ravi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Kaposiform hemangioendothelioma (KHE), a rare form of vascular neoplasm, is typically seen in children. In this paper, we report a unique case of KHE replacing bone marrow tissue mimicking myeloproliferative neoplasm with additional involvement in th
Externí odkaz:
https://doaj.org/article/ca671d0456104a77bfac7cf5262d5e25
Publikováno v:
F1000Research, Vol 5 (2016)
It was estimated that 59,340 new cases of head and neck cancer would be diagnosed in the US alone in 2015 and that 12,290 deaths would be attributed to the disease. Local and regional recurrences may be treated with chemotherapy and radiation; howeve
Externí odkaz:
https://doaj.org/article/9b2c2df4554d4963b52e0a4069a22029
Publikováno v:
Sarcoma, Vol 7, Iss 3-4, Pp 167-172 (2003)
Purpose: Radiation therapy in low and high doses is known to be associated with the occurrence of late secondary sarcomas. The addition of chemotherapy has not been clearly demonstrated as a contributing factor. We describe three patients with radiat
Externí odkaz:
https://doaj.org/article/d0148bdd52c44620a8c59505b20b2d8f
Autor:
Amandeep, Kaur, Kristine, Kuchta, William, Watkin, Megan, Sullivan, Lin, Liu, Pouya, Jamshidi, Nick, Campbell, Bruce, Brockstein, Ajit, Paintal
Publikováno v:
Archives of Pathology & Laboratory Medicine. 147:442-450
Context.— Pembrolizumab is used in patients with metastatic head and neck squamous cell carcinoma contingent upon the programmed death ligand-1 (PD-L1) combined positive score (CPS). Objective.— To compare PD-L1 CPS scores derived from paired res
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Stephanie Brenner, Tina M. Gremore, Bruce Brockstein, Laura S. Porter, Donald H. Baucom, David C. Atkins, Tamara Golden Sher, Tiffany Benfield
Publikováno v:
Supportive Care in Cancer. 29:3267-3275
To test feasibility and preliminary efficacy of a couple-based supportive communication (CSC) intervention for head and neck cancer (HNC) delivered during patients’ oncology treatment. Twenty couples were randomly assigned to either a four-session
Autor:
Kathleen Sullivan, Jason Kang, Abigail Harper, Bruce Brockstein, Brian R. Curtis, Nicholas P. Campbell, L. Kaminer, David L. Grinblatt, Cheryl C. Nocon, Menaka Sarav
Publikováno v:
JCO oncology practice. 17(3)
Autor:
Fay J. Hlubocky, David Cella, Mark J. Ratain, Bruce Brockstein, Christopher K. Daugherty, Lauren Hersch Nicholas, Bonnie J. Yap, Victoria S. Blinder, Kristen Wroblewski, Jeremy O'Connor, Fabiana S. Araújo, Jonas A. De Souza
Publikováno v:
Cancer. 123:476-484
BACKGROUND Cancer and its treatment lead to increased financial distress for patients. To the authors’ knowledge, to date, no standardized patient-reported outcome measure has been validated to assess this distress. METHODS Patients with AJCC Stage
Autor:
Ajit S Paintal, Bruce Brockstein
Publikováno v:
Head Neck Pathol
To evaluate the performance characteristics of PD-L1 immunohistochemistry (IHC) combined positive scoring (CPS) in core biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma (HNSqCCa). PD-L1 IHC using the SP263 an
Autor:
Peter J. O'Dwyer, Mark J. Ratain, Robert G. Maki, Stan B. Kaye, Charles M. Rudin, Gary K. Schwartz, David Khayat, Ahmad Awada, Joanna Vitfell-Rasmussen, Jennifer Obel, Maja DeJonge, Rebecca Kristeleit, Philippe L. Bedard, David R. D'Adamo, Ian B. Walters, Mark A. Dickson, Judith de Vos-Geelen, Samir D. Undevia, Jacek Jassem, Albiruni Ryan Abdul Razak, David Geary, Jacques Medioni, Jacques DeGreve, T.R. Jeffry Evans, Robin L. Jones, Michael B. Sawyer, Bruce Brockstein, Lillian L. Siu, Linda Janisch, Jean-François Baurain
Publikováno v:
European journal of cancer (Oxford, England : 1990), Vol. 120, p. 132-139 (2019)
European journal of cancer, 120
European Journal of Cancer, 120, 132-139. Elsevier Ltd.
European Journal of Cancer, 120, 132-139. ELSEVIER SCI LTD
European journal of cancer, 120
European Journal of Cancer, 120, 132-139. Elsevier Ltd.
European Journal of Cancer, 120, 132-139. ELSEVIER SCI LTD
Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43175dba0c26a55ee4ed2d4c6e2f81f8
https://hdl.handle.net/2078.1/237856
https://hdl.handle.net/2078.1/237856